CK1δ inhibitor SR-3029 potently inhibits tumor growth in broad subtypes of blood cancers. (A-E) SR-3029 potently inhibits viability of lymphomas. Lymphoma cell lines or primary lymphoma cells were treated with SR-3029 or DMSO control at the concentrations indicated on the x axis for 48 hours. Cell viability was quantitated using the Cell-Titer Glo (Promega) assay and is plotted on the y axis. Shown is the average of 3 experiments from the 48-hour treatment, presented as mean ± standard error of the mean. (F) A mouse xenograft model of human lymphoma was established using the Z-138 cell line in SCID beige mice. Tumor volume (y axis) is plotted against the time of treatment (x axis) for 2 treatment cohorts and the vehicle control. P values of the treatment cohorts vs control are indicated as determined by repeated-measure analysis of variance.